Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 9, 2005, Pages 3631-3639

  Nicolas, Olivier ^a   Margout, Delphine ^a   Taudon, Nicolas ^a   Wein, Sharon ^b   Calas, Michèle ^b   Vial, Henri J ^b   Bressolle, Françoise M M ^a  

^a UNIV MONTPELLIER   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,12 BIS[4 METHYL 5 (2 HYDROXYETHYL) 3 THIAZOL 3 IUM 3 YL]DODECANE DIBROMIDE; ANTIMALARIAL AGENT; BISTHIAZOLIUM SALT; CHLOROQUINE; LIOTHYRONINE; N 12 [FORMYL [1 [(2 OXO [1,3]OXATHIAN 4 YLIDENE)ETHYL]AMINO]DODECYL] N [1 (2 OXO [1,3]OXATHIAN 4 YLIDENE)ETHYL]FORMAMIDE; PRODRUG; TE 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; BODY WEIGHT; CHEMICAL MODIFICATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; IN VITRO STUDY; MALARIA FALCIPARUM; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VINCKEI; PRIORITY JOURNAL; STEADY STATE;

ANIMALS; ANTIMALARIALS; BAYES THEOREM; FEMALE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MALARIA; MICE; MODELS, BIOLOGICAL; PLASMODIUM; PLASMODIUM FALCIPARUM; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLES;

EID: 24144440791     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.9.3631-3639.2005     Document Type: Article

References (36)

1. Aarons, L. 1993. Sparse data analysis. Eur. J. Drug Metab. Pharmacokinet. 1:97-100.
2. Ancelin, M. L., M. Calas, J. Bompart, G. Cordina, D. Martin, M. Ben Bari, T. Jei, P. Druilhe, and H. J. Vial. 1998. Antimalarial activity of 77 phospholipid polar head analogs: close correlation between inhibition of phospholipid metabolism and in vitro Plasmodium falciparum growth. Blood 91:1426-1437.
3. Ancelin, M. L., M. Calas, A. Bonhoure, S. Herbute, and H. J. Vial. 2003. In vivo antimalarial activities of mono- and bis quaternary ammonium salts interfering with Plasmodium phospholipid metabolism. Antimicrob. Agents Chemother. 47:2598-2605.
4. Ancelin, M. L., M. Calas, V. Vidal-Sailhan, S. Herbute, P. Ringwald, and H. J. Vial. 2003. Potent inhibitors of Plasmodium phospholipid metabolism with a broad spectrum of in vitro antimalarial activities. Antimicrob. Agents Chemother. 47:2590-2597.
5. Barkan, D., H. Ginsburg, and J. Golenser. 2000. Optimisation of flow cytometric measurement of parasitaemia in Plasmodium-infected mice. Int. J. Parasitol. 30:649-653.
6. Beal, S. L., and L. B. Sheiner. 1994. NONMEM user's guide. University of California at San Francisco, San Francisco.
7. Biagini, A. G., E. Richier, P. G. Bray, M. Calas, H. Vial, and S. A. Ward. 2003. Heme binding contributes to antimalarial activity of bis-quaternary ammoniums. Antimicrob. Agents Chemother. 47:2584-2589.
8. Bois, F. Y. 1999. Analysis of PBPK models for risk characterization, p. 317-337. In A. J. Bailer, C. Maltoni, J. C. Bailar III, F. Belpoggi, J. V. Braizer, and M. Soffrintti (ed.), Uncertainty in the risk assessment of environmental and occupational hazards. New York Academy of Sciences, New York, N.Y.
9. Burtin, P., F. Mentré, J. Van Bree, and J. L. Steimer. 1996. Sparse sampling for assessment of drug exposure in toxicological studies. Eur. J. Metab. Pharmacokinet. 21:105-111.
10. Calas, M., M. L. Ancelin, G. Cordina, P. Portefaix, G. Piquet, V. Vidal-Sailhan, and H. Vial. 2000. Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipid metabolism: comparison between mono- and bisquaternary ammonium salts. J. Med. Chem. 43:505-516.
11. Calas, M., G. Cordina, J. Bompart, M. Ben Bari, T. Jei, M. L. Ancelin, and H. Vial. 1997. Antimalarial activity of molecules interfering with Plasmodium falciparum phospholipid metabolism. Structure-activity relationship analysis. J. Med. Chem. 40:3557-3566.
12. Desjardins, R. E., C. J. Canfield, J. D. Haynes, and J. D. Chulay. 1979. Quantitative assessment of antimalarial activity in vitro hy a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16:710-718.
13. Farenc, C., J. R. Fabreguette, and F. Bressolle. 2000. Pk-fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software. Comput. Biomed. Res. 33:315-330.
14. Greenwood, B., and T. Mutabingwa. 2002. Malaria in 2002. Nature 415:670-672.
15. Hing, J. P., S. G. Woolfrey, P. Greenslade, and P. M. C. Wright. 2001. Is mixed effect modeling or naïve pooled data analysis preferred for interpretation of single sample per subject toxicokinetic data? J. Pharmacokinet. Biopharm. 28:193-210.
16. Holz, G. G. 1977. Lipids and the malaria parasite. Bull. W. H. O. 55:237-248.
17. Mottu, F., A. Laurent, D. A. Rufenacht, and E. Doelker. 2000. Organic solvents for pharmaceutical parenterals and embolic liquids: a review of toxicity data. PDA J. Pharm. Sci. Technol. 54:456-469.
18. Mottu, F., M. J. Stelling, D. A. Rufenacht, and E. Doelker. 2001. Comparative hemolytic activity of undiluted organic water-miscible solvents for intravenous and intra-arterial injection. PDA J. Pharm. Sci. Technol. 55:16-23.
19. 18a. National Institutes of Health. 1985. Principles of laboratory animal care. NIH publication 85-23, revised. National Institutes of Health, Bethesda, Md.
20. Nicolas, O., C. Farenc, M. Calas, H. Vial, and F. Bressolle. 2005. Quantitation of antimalarial bis-thiazolium compounds and neutral bioprecursor in plasma by liquid chromatography-electrospray mass spectrometry. Clin. Chem. 51:593-603.
21. Nicolas, O., D. Margout, N. Taudon, M. Calas, H. Vial, and F. Bressolle. 2005. Liquid chromatography-electrospray mass spectrometry determination of a bis-thiazolium compound with potent antimalarial activity and its neutral bioprecursor in human plasma, whole blood and red blood cells. J. Chromatogr. B 820:83-93.
22. Olliaro, P. L., and Y. Yuthavong. 1999. An overview of chemotherapeutic targets for antimalarial drug discovery. Pharmacol. Ther. 81:91-110.
23. Research Development in Population Pharmacokinetics. 1998. Visual-NM user's manual, version 5.1. Research Development in Population Pharmacokinetics, Montpellier. France.
24. Research Development in Population Pharmacokinetics. 2000. Pk-fit software, version 2.1. Research Development in Population Pharmacokinetics. Montpellier, France.
25. Ridley, R. G. 2002. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415:686-693.
26. Sheiner, L. B., B. Rosenberg, and K. L. Melmon. 1972. Modelling of individual pharmacokinetics for computer-aided drugs dosage. Comput. Biomed. Res. 5:411-459.
27. Sherman, L. 1979. Biochemistry of Plasmodium (malarial parasites). Microbiol. Rev. 43:453-495.
28. Trager, W., and J. B. Jensen. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
29. Van Deenen, L. L. M., and J. De Gier. 1975. Lipids of the red cell membrane, p. 147-211. In G. Surgenor (ed.). The red blood cell. Academic Press, Inc., New York, N.Y.
30. Vial, H. 1996. Recent developments and rationale towards new strategies for malarial chemotherapy (a large review). Parasite 3:3-23.
31. Vial, H., and M. L. Ancelin. 1998. Malarial lipids, p. 159-175. In I. W. Sherman (e.d.), Malaria: parasite biology, biogenesis, protection. ASM Press, Washington, D.C.
32. Vial, H., M. Calas, J. J. Bourguignon, M. L. Ancelin, V. Vidal, and E. Rubi. Jan. 2001. Précurseurs de sels de bis-ammonium quaternaire et leurs applications comme prodrogues ayant une activité antiparasitaire. Patent 99 09471 applied by CNRS, 21 July 1999, WO 0105742 A1, published 25 January 2001.
33. Vial, H., P. Eldin, L. Tielens, and J. van Hellemond. 2003. Phospholipids in parasitic protozoa. Mol. Biochem. Parasitol. 126:143-154.
34. Vial, H. J., and M. Calas. 2001. Inhibitors of phospholipid metabolism, p. 347-365. In P. J. Rosenthal (ed.), Antimalarial chemotherapy, mechanism of action, modes of resistance, and new directions in drug development. Humana Press, Totowa, N.J.
35. Vial, H. J., S. Wein, C. Farenc, C. Kocken, O. Nicolas, M. L. Ancelin, F. Bressolle, A. Thomas, and M. Calas. 2004. Prodrugs of bisthiazolium salts are orally potent antimalarials. Proc. Natl. Acad. Sci. USA 101:15458-15463.
36. Wengelnik, K., V. Vidal, M. L. Ancelin, A. M. Cathiard, J. L. Morgat, C. H. Kocken, M. Calas, S. Herrera, A. W. Thomas, and H. J. Vial. 2002. A class of potent antimalarials and their specific accumulation in infected erythrocytes. Science 295:1311-1314.